Loading
A phase 1/2 trial of MT-125 run by Myosin Therapeutics Inc., not yet recruiting.
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma is a phase 1/2 interventional study registered as NCT07604285 by Myosin Therapeutics Inc., with 36 participants planned, started 2026-07. Conditions recorded: Glioblastoma. Interventions recorded: MT-125.
Shares MT-125, Myosin Therapeutics, Glioma & glioblastoma and the tag pipeline.
Shares Myosin Therapeutics and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/